Special Issue "Advances in Marine Chitin and Chitosan II, 2017"
A special issue of Marine Drugs (ISSN 1660-3397).
Deadline for manuscript submissions: closed (31 January 2017)
As a result of our call in 2014 for submissions to a Special Issue, Advances in Marine Chitin and Chitosan in Marine Drugs, we are now pleased to tell you that this issue has been published. Twenty high class papers were included in this issue, which we now plan to publish as a book. In addition we now seek to publish a further Special Issue, Advances in Marine Chitin and Chitosan II, 2017, in Marine Drugs. As before, we plan to produce a strong, very exciting issue that will encompass breakthroughs in high value, scientific and industrial chitin and chitosan research. Despite significant advances in chitin and chitosan research since the 1970s, current overviews in recent publications involving chitin and chitosan research advances need reporting.
We look forward very much to your input.
Dr. Hitoshi Sashiwa,
Prof. Dr. David Harding,
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- chemical modification
- controlled drug delivery
- tissue engineering
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Author: Jaehwi Lee, PhD
Affiliation: Professor of Pharmaceutics and Drug Delivery, College of Pharmacy, Chung-Ang University, Seoul 06974, Korea
Abstract: Chitosan has widely been used as a key biomaterial for the development of drug delivery systems intended to be administered via oral and parenteral routes. Especially, chitosan-based microparticles are the most frequently employed dosage forms for the delivery of drugs into the body, along with conventional and specialized delivery systems such as hydrogels, nanoparticle and thin films. Based on the progress made to chitosan-based drug delivery systems, the usefulness of the chitosan has been further expanded to anti-cancer chemoembolization, tissue engineering, and stem cell research. For instance, due to advantageous features of chitosan such as biocompatibility and biodegradability, chitosan has been used to develop embolic materials designed to efficiently occlude the blood vessel by which the tumor tissues are supplied with oxygen and nutrients. Indeed, chitosan microspheres have been reported to be as a promising embolic material. For better anti-cancer effect chitosan microspheres that can locally release anti-cancer drugs was proposed. In addition, a complex of radioactive materials and chitosan to be locally injected into the liver has been investigated as an efficient therapeutic tool for hepatocellular carcinoma. Like this, a number of attempts have been explored to use chitosan-based carriers for the delivery of various agents especially to the specific site of the body. Thus, in this work, case studies where chitosan-based drug delivery systems have successfully been used for the local delivery of therapeutic agents will be presented together with future research and development efforts.